BOC-3-(三氟甲基)-D-苯丙氨酸 | 82317-82-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: BOC-3-(三氟甲基)-D-苯丙氨酸
• 中文别名: BOC-D-3-三氟甲基苯丙氨酸；N-叔丁氧羰基-D-3-三氟甲基苯丙氨酸
• 英文名称: ((R)-2-(tert-butoxycarbonyl)amino)-3-(3-(trifluoromethyl)phenyl)propanoic acid
• 英文别名: Boc-3-(trifluoromethyl)-D-phenylalanine；(2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[3-(trifluoromethyl)phenyl]propanoic acid
• CAS: 82317-82-6
• 化学式: C₁₅H₁₈F₃NO₄
• mdl: MFCD00672525
• 分子量: 333.307
• InChiKey: SHMWDGGGZHFFRC-LLVKDONJSA-N

物化性质

• 稳定性/保质期：
  如果按照规范使用和储存，则不会发生分解，并且没有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.466
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  BOC-3-(三氟甲基)-D-苯丙氨酸 在 silver benzoate 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 [(R)-3-Oxo-3-thiazolidin-3-yl-1-(3-trifluoromethyl-benzyl)-propyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  发现有效的和选择性的基于β-高苯丙氨酸的二肽基肽酶IV抑制剂。

  摘要：

  内部筛选铅β-氨基酰基脯氨酸8的修饰得到了等价的噻唑烷化物9。对9的苯环的广泛SAR研究导致发现了一系列新的有效的和选择性的DP-IV抑制剂。事实证明，在2位上引入氟对于该系列的效能至关重要。2,5-二氟（22q）和2,4,5-三氟（22t）类似物是DP-IV的有效抑制剂（分别为IC（50）= 270、119nM）。

  DOI：

  10.1016/j.bmcl.2004.06.099
• 作为产物：
  描述：

  diethyl α-acetamido, α-(3-trifluoromethylbenzyl)malonate 在 盐酸 、 sodium hydroxide 、 三氟化硼乙醚 、 magnesium oxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 生成 BOC-3-(三氟甲基)-D-苯丙氨酸
  参考文献：
  名称：

  Synthesis and biological activity of some very hydrophobic superagonist analogs of luteinizing hormone-releasing hormone

  摘要：

  The effect of increased hydrophobicity at position 6 of luteinizing hormone-releasing hormone (LH-RH) has been investigated by the incorporation of a series of 15 very hydrophobic, unnatural D-amino acids at this position. The unnatural amino acids studied can be considered analogues of phenylalanine with carbocyclic aromatic side chains consisting of substituted phenyl (e.g., 2,4,6-trimethylphenyl, p-biphenyl) or polycyclic aromatic (e.g., naphthalene, anthracene) units. When enzymatic resolution (subtilisin Carlsberg) of the most hydrophobic amino acids failed, the racemic amino acids were incorporated, and the diastereomeric LH-RH analogues were resolved by preparative high-performance liquid chromatography. The analogues were synthesized by the solid-phase technique. All of the synthetic compounds were very potent LH-RH superagonists, but [6-(3-(2-naphthyl)-D-alanine)]LH-RH, [6-(3-(2-naphthyl)-D-alanine), 7-(N alpha-methylleucine)]LH-RH and [6-(3-(2,4,6-trimethylphenyl)-D-alanine)]LH-RH appear to be among the most potent LH-RH agonist analogues yet reported when tested in a rat estrus cyclicity suppression assay designed to show the paradoxical antifertility effects of these compounds [ED50 approximately 7 x 10(-8) g; twice daily in saline]. These analogues are twice as potent as [D-Trp6,ProNHEt9]LH-RH in this assay system (i.e., approximately 200 times the potency of LH-RH).

  DOI：

  10.1021/jm00349a006

文献信息

• Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
  申请人：D'Sidocky Neil R.

  公开号：US20080242694A1

  公开（公告）日：2008-10-02

  Provided herein are Heterocyclic Compounds having the following structure: wherein R 1 , R 2 , X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

  本文提供具有以下结构的杂环化合物： 其中R1、R2、X、Y和Z如本文所定义，包含有效量杂环化合物的组合物，以及治疗或预防癌症、炎症性疾病、免疫疾病、代谢性疾病以及通过给予患者需要的有效量杂环化合物来抑制激酶途径治疗或预防的疾病的方法。
• Dual Catalytic Decarboxylative Allylations of α-Amino Acids and Their Divergent Mechanisms
  作者：Simon B. Lang、Kathryn M. O'Nele、Justin T. Douglas、Jon A. Tunge

  DOI：10.1002/chem.201503644

  日期：2015.12.14

  The room temperature radical decarboxylative allylation of N‐protected α‐amino acids and esters has been accomplished via a combination of palladium and photoredox catalysis to provide homoallylic amines. Mechanistic investigations revealed that the stability of the α‐amino radical, which is formed by decarboxylation, dictates the predominant reaction pathway between competing mechanisms.

  N保护的α-氨基酸和酯在室温下进行自由基脱羧烯丙基化反应，是通过钯和光氧化还原催化作用的组合来实现的，以提供均胺基胺。机理研究表明，由脱羧作用形成的α-氨基自由基的稳定性决定了竞争机制之间的主要反应途径。
• Modulators of serotonin receptors
  申请人：Wacker A. Dean

  公开号：US20050080074A1

  公开（公告）日：2005-04-14

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了血清素受体调节剂，包含这些调节剂的药物组合物以及治疗与血清素受体调节相关的各种疾病、症状和疾患的方法，例如：代谢性疾病，包括但不限于肥胖、糖尿病、糖尿病并发症、动脉粥样硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑、抑郁、强迫症、恐慌症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。
• Structure-Activity Relationship Studies on (<i>R</i>)-PFI-2 Analogues as Inhibitors of Histone Lysine Methyltransferase SETD7
  作者：Danny C. Lenstra、Eddy Damen、Ruben G. G. Leenders、Richard H. Blaauw、Floris P. J. T. Rutjes、Anita Wegert、Jasmin Mecinović

  DOI：10.1002/cmdc.201800242

  日期：2018.7.18

  report structure–activity relationship studies on (R)‐PFI‐2 and its analogues. A library of 29 structural analogues of (R)‐PFI‐2 was synthesized and evaluated for inhibition of recombinantly expressed human SETD7. The key interactions were found to be a salt bridge and a hydrogen bond formed between (R)‐PFI‐2′s NH2+ group and SETD7′s Asp256 and His252 residue, respectively.

  SETD7是一种参与人类基因调控的组蛋白H3K4赖氨酸甲基转移酶。SETD7的异常表达与多种疾病有关，包括癌症。因此，SETD7被认为是开发新的表观遗传药物的良好靶标。迄今为止，鲜有报道报道靶向SETD7的选择性小分子抑制剂很少，最有效的是（R）-PFI-2。在此，我们报告了对（R）-PFI-2及其类似物的结构-活性关系研究。合成了（R）-PFI-2的29个结构类似物的文库，并评估了其对重组表达的人SETD7的抑制作用。发现关键的相互作用是盐桥和（R）-PFI-2的NH 2 +之间形成氢键 组和SETD7的Asp256和His252残基。
• [EN] MODULATORS OF SEROTONIN RECEPTORS<br/>[FR] MODULATEURS DES RECEPTEURS DE LA SEROTONINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005035533A1

  公开（公告）日：2005-04-21

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了5-羟色胺受体调节剂、含有这种调节剂的药物组合物以及使用这些化合物和组合物治疗与5-羟色胺受体调节相关的各种疾病、病症和疾患的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑症、抑郁症、强迫症、惊恐症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。